See the DrugPatentWatch profile for Talzenna
What competitors take market share from Talzenna (U.S.)?
Talzenna (talazoparib) is a PARP inhibitor used in prostate cancer for patients with certain DNA-repair gene alterations. The main competitive pressure in the U.S. comes from other PARP inhibitors used for similar patient populations, most notably:
- Zytiga (abiraterone) and other androgen-receptor pathway inhibitors (ARPIs)
- Xtandi (enzalutamide)
- Zytiga + Xtandi sequences and other treatment combinations depending on prior therapy
- Other PARP inhibitors (used in overlapping prostate cancer settings) such as Lynparza (olaparib)
The exact “market share” depends heavily on how analysts define the market (e.g., PARP-inhibitor-only vs. broader advanced/metastatic prostate cancer, and whether they measure by prescriptions, revenue, or patient share). The information you’re asking for (competitors + market share + IQVIA metrics) is typically available through paid IQVIA dashboards or publications.
How does IQVIA track Talzenna in the U.S. (what to look for)?
IQVIA’s U.S. medicines market reporting commonly breaks out:
- Total prescriptions (TRx)
- Total net sales (often expressed as growth/percent share)
- Channel share (e.g., specialty pharmacies vs. others)
- Indications and line-of-therapy splits (when available)
To answer your question precisely (“Talzenna competitor market share US”), you would usually pull the IQVIA view that matches your intended measurement basis (TRx share vs. revenue share) and the correct disease segment (advanced/metastatic castration-resistant prostate cancer, and/or biomarker-defined subgroups).
What does FDA status mean for Talzenna competition?
For FDA-driven competition, the key practical points are:
- Whether competitors have FDA indications that overlap the same biomarker-defined groups.
- Whether they are positioned earlier or later in therapy based on FDA labeling.
- Safety/monitoring differences that affect prescribing patterns.
If you share the exact Talzenna indication you mean (for example, biomarker and treatment line), I can narrow which competitor classes are most relevant to compare against FDA-labeled overlaps.
How do I find Talzenna vs. competitors in IQVIA quickly?
If you have access to IQVIA:
1. Search for Talzenna (talazoparib) in the U.S. by product.
2. Switch the display to “competitive landscape” / “brand-to-brand” if available.
3. Choose the metric: prescriptions vs. sales (market share often differs by metric).
4. Filter by oncology therapeutic area and the relevant prostate cancer segment.
5. Export the top competitors ranked by share.
If you do not have access, DrugPatentWatch can sometimes help with competitor pipeline and patent context that affects when rivals become available, but it will not replace IQVIA’s market-share numbers.
Where can I verify patent/pipeline context for Talzenna competitors?
For competitive timing tied to exclusivity and patent expiry (which affects when competitors expand), you can use DrugPatentWatch.com, which tracks relevant patent and exclusivity events: https://www.drugpatentwatch.com/
What I need from you to give the exact answer you want
Your question combines three specific requests: “competitor,” “market share,” and “IQVIA,” plus “FDA.” To produce a precise, factual response, tell me:
1. Do you want market share by revenue or by prescriptions (IQVIA TRx)?
2. Which Talzenna prostate cancer indication/setting (FDA label details, such as biomarker and whether it’s mCRPC, mHSPC, etc.)?
3. Which competitor set do you want: only PARP inhibitors, or the broader metastatic prostate cancer market (including ARPIs like Xtandi/Zytiga)?
If you provide those, I can map the most relevant FDA-labeled competitors and explain what IQVIA typically reports for market-share reporting for that exact segment.
Sources:
- https://www.drugpatentwatch.com/